AMENDMENTS TO THE CLAIMS

A complete listing of all claims is presented below with insertions underlined (e.g., insertion), and deletions struckthrough or in double brackets (e.g., ~~deletion~~ or [[deletion]]):

1.-13. **(Cancelled)**

14. **(Currently Amended)** A prosthesis for placement at an opening from a main body lumen to a branch body lumen, the prosthesis comprising:

a radially expansible support, the support configured to be deployed in at least a portion of the branch body lumen**, the support adapted to provide a first radial force to support a body lumen**;

at least two elongate, flexible fronds each having a first end, a second end and a**n axially extending undulating elongate portion having a plurality of crests and troughs between the first and second ends** ~~length in between~~, **at least a portion of the elongate portion comprising a plurality of spaced apart filaments having crests and troughs extending in-phase,** the fronds extending from an end of the support and configured to be positioned across the Os and into the main body lumen; ~~and~~

at least one circumferential link **comprising an undulating pattern including a plurality of crests and troughs, the circumferential link being** connected **at crests thereof** to the second ends of the fronds, the circumferential link spaced axially apart from the support by the fronds **and adapted to provide a second radial force that is less than the first radial force; and**

a plurality of elongate side wall openings in between adjacent fronds sized and configured to receive a stent deployment device therethrough;

the elongate, flexible fronds, the support and the circumferential link defining a unitary body as deployed, ~~having~~ **the** elongate side wall openings in between adjacent fronds for facilitating crossing of a main vessel stent therethrough when the support is positioned in the branch body lumen and the circumferential link is positioned in the main body lumen.

15. (**Previously Presented**) The prosthesis as in Claim 14, wherein the circumferential link comprises an undulating pattern having at least three apexes.

16. (**Previously Presented**) The prosthesis as in Claim 14, comprising three fronds.

17. (**Previously Presented**) The prosthesis as in Claim 14, wherein at least one frond comprises a helical configuration.

18. (**Original**) The prosthesis as in Claim 17, comprising a plurality of helical fronds.

19. (**Previously Presented**) The prosthesis as in Claim 14, wherein at least a portion of the fronds comprises a lubricous coating.

20. (**Previously Presented**) The prosthesis as in Claim 14, wherein the fronds, have an axial length of at least about 8 mm.

21. (**Original**) The prosthesis as in Claim 14, wherein the circumferential link is radiopaque.

22. (**Previously Presented**) The prosthesis as in Claim 21, wherein the circumferential link has a greater radiopacity than the fronds.

23. (**Original**) The prosthesis as in Claim 14, comprising an endothelial cell ingrowth surface.

24. (**Original**) The prosthesis as in Claim 14, comprising a non thrombogenic surface.

25.-29. (**Cancelled**)

30.-35. (**Cancelled**)

36. (**Previously Presented**) The prosthesis as in Claim 14, wherein at least one frond comprises a plurality of parallel, undulating filaments.

37. **(Previously Presented)** The prosthesis as in Claim 36, wherein at least a portion of the radially expansible support comprises a drug coating, and at least a portion of the fronds and the circumferential link are without a drug coating.

38. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating is configured to produce at least one of a controlled drug release rate, a constant drug release rate, bi-modal drug release rate or a controlled concentration of drug proximate a target vessel wall.

39. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug is one of an anti-cell prolifertive, anti cell migration, anti-neo plastic, and anti inflammatory drug.

40. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug is configured to reduce restensosis.

41. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating includes a first coating and a second coating.

42. **(Previously Presented)** The prosthesis as in Claim 41, wherein the first coating is configured to produce a first drug release rate and the second coating is configured to produce a second drug release rate.

43. **(Previously Presented)** The prosthesis as in Claim 14, wherein the circumferential link comprises a single transverse filament.

44. **(Previously Presented)** The prosthesis as in Claim 14, further comprising a transition section between the support and the fronds.

45.-46. **(Cancelled)**

47. **(Previously Presented)** The prosthesis of Claim 14, wherein the prosthesis includes a drug incorporated into a polymer matrix.

48. **(Cancelled)**

49. (**Previously Presented**) The prosthesis of Claim 47, wherein the polymer matrix includes a base layer and a top layer, the drug being incorporated into at least one of the top layer and the base layer.

50. (**Previously Presented**) The prosthesis of Claim 14, wherein the prosthesis includes one or more reservoirs configured to be loaded with a drug.

51. (**Previously Presented**) The prosthesis of Claim 50, wherein the prosthesis includes one or more drugs in the one or more reservoirs.